KREBSBIO

Krebs Biochemicals & Industries Share Price

₹83.25 +0.15 (0.18%)

21 Nov, 2024 14:15

SIP TrendupStart SIP in KREBSBIO

Start SIP

Performance

  • Low
  • ₹82
  • High
  • ₹86
  • 52 Week Low
  • ₹60
  • 52 Week High
  • ₹122
  • Open Price₹83
  • Previous Close₹83
  • Volume19,234

Investment Returns

  • Over 1 Month + 1.52%
  • Over 3 Month + 1.22%
  • Over 6 Month + 22.07%
  • Over 1 Year + 3.42%
SIP Lightning

Smart Investing Starts Here Start SIP with Krebs Biochemicals & Industries for Steady Growth!

Invest Now

Krebs Biochemicals & Industries Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -8.3
  • PEG Ratio
  • 4.9
  • Market Cap Cr
  • 180
  • P/B Ratio
  • -1.5
  • Average True Range
  • 5
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.07
  • RSI
  • 47.23
  • MFI
  • 57.01

Krebs Biochemicals & Industries Financials

Krebs Biochemicals & Industries Technicals

EMA & SMA

Current Price
₹83.25
+ 0.15 (0.18%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹84.70
  • 50 Day
  • ₹83.85
  • 100 Day
  • ₹82.41
  • 200 Day
  • ₹80.20

Resistance and Support

83.78 Pivot Speed
  • R3 91.77
  • R2 89.33
  • R1 86.22
  • S1 80.67
  • S2 78.23
  • S3 75.12

What's your outlook on Krebs Biochemicals & Industries?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Krebs Biocs.& Inds. has an operating revenue of Rs. 50.69 Cr. on a trailing 12-month basis. An annual revenue de-growth of -4% needs improvement, Pre-tax margin of -39% needs improvement, ROE of 0% is poor and needs improvement. NULL The stock from a technical standpoint is trading below to its 50DMA and around 7% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 14 which is a POOR score indicating inconsistency in earnings, a RS Rating of 55 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Krebs Biochemicals & Industries Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results & Other To Consider Other business matters.
2024-08-07 Quarterly Results
2024-05-21 Audited Results
2024-02-12 Quarterly Results
2023-11-08 Quarterly Results

Krebs Biochemicals & Industries F&O

Krebs Biochemicals & Industries Shareholding Pattern

72.74%
0.5%
19.8%
6.96%

About Krebs Biochemicals & Industries

  • NSE Symbol
  • KREBSBIO
  • BSE Symbol
  • 524518
  • Managing Director & CEO
  • Mr. Jitendra Shah
  • ISIN
  • INE268B01013

Similar Stocks to Krebs Biochemicals & Industries

Krebs Biochemicals & Industries FAQs

Krebs Biochemicals & Industries share price is ₹83 As on 21 November, 2024 | 14:01

The Market Cap of Krebs Biochemicals & Industries is ₹179.5 Cr As on 21 November, 2024 | 14:01

The P/E ratio of Krebs Biochemicals & Industries is -8.3 As on 21 November, 2024 | 14:01

The PB ratio of Krebs Biochemicals & Industries is -1.5 As on 21 November, 2024 | 14:01

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23